Paroxetine mesylate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2003
- First approval year
- 2003
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Paroxetine mesylate
- Molecular weight
- 425.48
- Structure (SMILES)
- CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
- brisdelle
- Brisdelle
- pexeva
- Pexeva
- (-)-TRANS-4R-(4'-FLUOROPHENYL)-3S-((3',4'-METHYLENEDIOXYPHENOXY)METHYL)PIPERIDINE, MESILATE
- (-)-TRANS-4R-(4'-FLUOROPHENYL)-3S-((3',4'-METHYLENEDIOXYPHENOXY)METHYL)PIPERIDINE, MESYLATE
- mesafem
- Mesafem
- paroxetine mesilate
- Paroxetine mesilate
- PAROXETINE MESILATE [MART.]
- Paroxetine mesilate [WHO-DD]
- paroxetine mesilate mart
- paroxetine mesilate who dd
- paroxetine mesylate
- Paroxetine mesylate
- PAROXETINE MESYLATE [ORANGE BOOK]
- PAROXETINE MESYLATE [USAN]
- paroxetine mesylate orange book
- paroxetine mesylate usan
- paroxetine methanesulfonate
- Paroxetine methanesulfonate
- PAROXETINE METHANESULFONATE [MI]
- paroxetine methanesulfonate mi
- paroxetine methanesulphonate
- Paroxetine methanesulphonate
- po t mes
- PO-T.MES
- pot mes
And 3 more, listed on the interactive page.
- CAS registry numbers
- 217797-14-3
- ChEMBL ID
- CHEMBL1200609
- InChIKey
- SHIJTGJXUHTGGZ-RVXRQPKJSA-N
- FDA ingredient codes (UNII)
- M711N184JE
- 9845306
- 11407639
- 235830
- 436212
- Applicant
- LEGACY
- Approval date
- 28 Jun 2013
- Application number
- NDA204516
- Patents
- 3
- Designations
- 0
- Earliest recorded loss of exclusivity
- 6 Apr 2029
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Drug name stem
- -oxetine
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Serotonin transporter inhibitor
- Action type
- Inhibitor
- Target
- Sodium-dependent serotonin transporter
- Protein identifier
- P31645
Open Targets mechanisms
- Mechanism
- Serotonin transporter inhibitor
- Action type
- Inhibitor
- Target
- Sodium-dependent serotonin transporter
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Obsessive-Compulsive Disorder
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004242
- Subject identifier
- D009771
- Condition
- Panic Disorder
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004262
- Subject identifier
- D016584
- Condition
- Anxiety Disorders
- Highest recorded phase
- 4
- Condition identifier
- EFO:0006788
- Subject identifier
- D001008
- Condition
- Phobia, Social
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001917
- Subject identifier
- D000072861
- Condition
- Menopause
- Highest recorded phase
- 4
- Condition identifier
- GO:0042697
- Subject identifier
- D008593
- Condition
- Hot Flashes
- Highest recorded phase
- 3
- Condition identifier
- HP:0031217
- Subject identifier
- D019584
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition identifier
- EFO_0001358
- Condition identifier
- EFO_0004242
- Condition identifier
- EFO_0004262
- Condition identifier
- EFO_0006788
- Condition identifier
- EFO_1001917
- Condition identifier
- GO_0042697
- Condition identifier
- GO_0042697
- Highest recorded phase
- 4
- Condition identifier
- HP_0031217
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001247
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0002009
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005146
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005383
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005618
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0008114
- Highest recorded phase
- 4
Warnings
- Warning
- Black Box Warning
- Effect
- psychiatric toxicity
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- psychiatric toxicity
- Country
- United States
- Event
- aggression
- Reports
- 104
- Reporting signal score
- 117.865
- Event
- agitation
- Reports
- 182
- Reporting signal score
- 221.353
- Event
- agoraphobia
- Reports
- 21
- Reporting signal score
- 75.1559
- Event
- anxiety
- Reports
- 225
- Reporting signal score
- 163.036
- Event
- atrial septal defect
- Reports
- 56
- Reporting signal score
- 100.531
- Event
- bradykinesia
- Reports
- 30
- Reporting signal score
- 60.114
- Event
- bradyphrenia
- Reports
- 68
- Reporting signal score
- 164.311
- Event
- cardiopulmonary failure
- Reports
- 27
- Reporting signal score
- 93.9565
- Event
- clonus
- Reports
- 36
- Reporting signal score
- 89.97
- Event
- coma
- Reports
- 165
- Reporting signal score
- 249.913
- Event
- confusional state
- Reports
- 275
- Reporting signal score
- 278.618
- Event
- delirium
- Reports
- 67
- Reporting signal score
- 56.3207
- Event
- depression
- Reports
- 169
- Reporting signal score
- 87.6725
- Event
- disorientation
- Reports
- 79
- Reporting signal score
- 80.5005
- Event
- disturbance in attention
- Reports
- 78
- Reporting signal score
- 85.3862
- Event
- drug abuse
- Reports
- 399
- Reporting signal score
- 848.463
- Event
- drug interaction
- Reports
- 357
- Reporting signal score
- 336.67
- Event
- drug withdrawal syndrome
- Reports
- 132
- Reporting signal score
- 183.972
- Event
- dyskinesia
- Reports
- 59
- Reporting signal score
- 55.5348
- Event
- dystonia
- Reports
- 50
- Reporting signal score
- 66.3102
- Event
- electrocardiogram qt prolonged
- Reports
- 108
- Reporting signal score
- 119.549
- Event
- emotional disorder
- Reports
- 41
- Reporting signal score
- 58.429
- Event
- extrapyramidal disorder
- Reports
- 83
- Reporting signal score
- 143.557
- Event
- fall
- Reports
- 217
- Reporting signal score
- 70.2805
- Event
- hallucination, auditory
- Reports
- 49
- Reporting signal score
- 69.2265
And 22 more, listed on the interactive page.
- NCT00786188
- NCT01101841
- NCT01361308
- NCT01829919
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 39.72
- Calculated partition coefficient (ALogP)
- 3.33
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 29
- Molecular formula
- C20H24FNO6S
- Monoisotopic mass
- 425.13083682
- Natural product
- No
- 0574-0279
- 43547-409
- 83107-027
Related records
Trials (187)
- 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A Combination Therapy In Patients With Social Anxiety Disorder
- A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
- A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers
- A Local Register Study For Major Depression Of Paroxetine Controlled Release
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
- A Phase I Study of NS-079 in Healthy Participants
- A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
- A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
- A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity
- A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects
- A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks
- A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
Approved for (6)
- Anxiety disorder
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Post-traumatic stress disorder
- Social phobia
Targets (1)
- SLC6A4 Serotonin transporter inhibitor